Grant funding can be a catalyst for scientific and commercial progress. Adriann Sax, CEO & Co-Founder of Vetigenics, shares how strategic use of SBIR and foundation grants enabled the company to build a canine antibody platform, attract support from investors, and secure partners such as Merck Animal Health.

A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.